Please ensure Javascript is enabled for purposes of website accessibility

Cheap Viagra On the Way

By Dave Williamson - Dec 27, 2013 at 7:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Is a cheap generic version of the famous little blue pill finally just around the corner?

In this segment of the Motley Fool's Market Check-Up, Fool health-care analyst David Williamson takes investors through some of the biggest stories affecting Big Pharma, biotech stocks, and the health insurance industry today.

Pfizer (PFE 3.00%) has come to terms with generic drugmaker Teva Pharmaceuticals (TEVA 0.91%) over its erectile dysfunction drug Viagra, with Teva due to launch its generic version two years early in 2017. As this will be earlier than Pfizer's patent expiration on the drug, Teva will be paying Pfizer an undisclosed royalty on sales, which should mitigate some of the damage the generic competitor would do. In this video, David tells investors why he thinks this is a great deal for Teva going forward, and talks about the most important catalyst for Pfizer investors on the horizon today.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$51.59 (3.00%) $1.50
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$7.74 (0.91%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.